Atherosclerotic renal artery stenosis: Current status

Advances in Chronic Kidney Disease

Volumn 22, Issue 3, 2015, Pages 224-231

  Kwon, Soon Hyo ^a,b   Lerman, Lilach O ^a,b  

^a MAYO CLINIC   (United States)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Hypertension; Inflammation; Ischemia; Renal artery obstruction

Indexed keywords

ATHEROSCLEROTIC RENAL ARTERY STENOSIS; BOLD SIGNAL; DOPPLER ECHOGRAPHY; ELASTOGRAPHY; ENDOTHELIAL PROGENITOR CELL; FIBROSIS; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; MICROANGIOPATHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULARIZATION; ATHEROSCLEROSIS; COMPLICATION; DIAGNOSTIC IMAGING; HYPERTENSION; KIDNEY; METABOLISM; PATHOLOGY; RENAL ARTERY OBSTRUCTION;

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; KIDNEY; MAGNETIC RESONANCE IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; RENAL ARTERY OBSTRUCTION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84928017980     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.10.004     Document Type: Review

References (86)

1. Hansen K.J., Edwards M.S., Craven T.E., et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002, 36(3):443-451.
2. Guo H., Kalra P.A., Gilbertson D.T., et al. Atherosclerotic renovascular disease in older US patients starting dialysis, 1996 to 2001. Circulation 2007, 115(1):50-58.
3. Ebrahimi B., Li Z., Eirin A., Zhu X.Y., Textor S.C., Lerman L.O. Addition of endothelial progenitor cells to renal revascularization restores medullary tubular oxygen consumption in swine renal artery stenosis. Am J Physiol Renal Physiol 2012, 302(11):F1478-F1485.
4. Krier J.D., Ritman E.L., Bajzer Z., Romero J.C., Lerman A., Lerman L.O. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol 2001, 281(4):F630-F638.
5. Chade A.R., Zhu X.Y., Krier J.D., et al. Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells 2010, 28(6):1039-1047.
6. Vashist A., Heller E.N., Brown E.J., Alhaddad I.A. Renal artery stenosis: a cardiovascular perspective. Am Heart J 2002, 143(4):559-564.
7. Cheung C.M., Patel A., Shaheen N., et al. The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract 2007, 107(2):c35-c42.
8. Chrysochou C., Foley R.N., Young J.F., Khavandi K., Cheung C.M., Kalra P.A. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant 2012, 27(4):1403-1409.
9. Wheatley K., Ives N., Gray R., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009, 361(20):1953-1962.
10. Valluri A., Severn A., Chakraverty S. Do patients undergoing renal revascularization outside of the ASTRAL trial show any benefit? Results of a single-centre observational study. Nephrol Dial Transplant 2012, 27(2):734-738.
11. Bax L., Woittiez A.J., Kouwenberg H.J., et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009, 150(12):840-848. W150-W151.
12. Cooper C.J., Murphy T.P., Cutlip D.E., et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014, 370(1):13-22.
13. Caielli P., Frigo A.C., Pengo M.F., et al. Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrol Dial Transplant 2015, 30(4):541-553.
14. Shetty R., Biondi-Zoccai G.G., Abbate A., Amin M.S., Jovin I.S. Percutaneous renal artery intervention versus medical therapy in patients with renal artery stenosis: a meta-analysis. EuroIntervention 2011, 7(7):844-851.
15. Kumbhani D.J., Bavry A.A., Harvey J.E., et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J 2011, 161(3):622-630.
16. Lerman L.O., Taler S.J., Textor S.C., Sheedy P.F., Stanson A.W., Romero J.C. Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. Kidney Int 1996, 49(3):846-854.
17. Suresh M., Laboi P., Mamtora H., Kalra P.A. Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant 2000, 15(5):631-636.
18. Gloviczki M.L., Lerman L.O., Textor S.C. Blood oxygen level-dependent (BOLD) MRI in renovascular hypertension. Curr Hypertens Rep 2011, 13(5):370-377.
19. Cheung C.M., Chrysochou C., Shurrab A.E., Buckley D.L., Cowie A., Kalra P.A. Effects of renal volume and single-kidney glomerular filtration rate on renal functional outcome in atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010, 25(4):1133-1140.
20. Kaissling B., Lehir M., Kriz W. Renal epithelial injury and fibrosis. Biochim Biophys Acta 2013, 1832(7):931-939.
21. Mimura I., Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 2010, 6(11):667-678.
22. Alhadad A., Guron G., Fortuna-Nowakowska E., et al. Renal angioplasty causes a rapid transient increase in inflammatory biomarkers, but reduced levels of interleukin-6 and endothelin-1 1 month after intervention. J Hypertens 2007, 25(9):1907-1914.
23. Chade A.R., Rodriguez-Porcel M., Herrmann J., et al. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol 2004, 15(4):958-966.
24. Lerman L.O., Nath K.A., Rodriguez-Porcel M., et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001, 37(2 Pt 2):541-546.
25. Calo L.A., Schiavo S., Davis P.A., et al. Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. J Hypertens 2010, 28(1):111-118.
26. Muller D.N., Dechend R., Mervaala E.M., et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000, 35(1 Pt 2):193-201.
27. Turnbull F., Neal B., Pfeffer M., et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007, 25(5):951-958.
28. Crowley S.D., Vasievich M.P., Ruiz P., et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119(4):943-953.
29. Crowley S.D., Tharaux P.L., Audoly L.P., Coffman T.M. Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 2004, 181(4):561-570.
30. Benigni A., Corna D., Zoja C., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009, 119(3):524-530.
31. Rompe F., Artuc M., Hallberg A., et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010, 55(4):924-931.
32. Zhang X., Eirin A., Li Z.L., et al. Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney. Kidney Int 2013, 84(4):767-775.
33. Zhang X., Li Z.L., Crane J.A., et al. Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension. Hypertension 2014, 64(1):87-93.
34. Marvar P.J., Thabet S.R., Guzik T.J., et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 2010, 107(2):263-270.
35. Zhang J.D., Patel M.B., Song Y.S., et al. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 2012, 110(12):1604-1617.
36. Zhu X.Y., Chade A.R., Rodriguez-Porcel M., et al. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24(10):1854-1859.
37. Eirin A., Zhu X.Y., Li Z., et al. Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis. Arterioscler Thromb Vasc Biol 2013, 33(5):1006-1013.
38. Noh H., Ha H. Reactive oxygen species and oxidative stress. Contrib Nephrol 2011, 170:102-112.
39. Pialoux V., Mounier R., Brown A.D., Steinback C.D., Rawling J.M., Poulin M.J. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med 2009, 46(2):321-326.
40. Zhu X.Y., Chade A.R., Krier J.D., et al. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 2009, 27(10):2063-2073.
41. Eirin A., Zhu X.Y., Krier J.D., et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells 2012, 30(5):1030-1041.
42. Palm F., Onozato M., Welch W.J., Wilcox C.S. Blood pressure, blood flow, and oxygenation in the clipped kidney of chronic 2-kidney, 1-clip rats: effects of tempol and angiotensin blockade. Hypertension 2010, 55(2):298-304.
43. Eirin A., Li Z., Zhang X., et al. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension 2012, 60(5):1242-1249.
44. Myung S.K., Ju W., Cho B., et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013, 346:f10.
45. Lerman L.O., Textor S.C., Grande J.P. Mechanisms of tissue injury in renal artery stenosis: ischemia and beyond. Prog Cardiovasc Dis 2009, 52(3):196-203.
46. Eirin A., Lerman L.O. Darkness at the end of the tunnel: poststenotic kidney injury. Physiology (Bethesda) 2013, 28(4):245-253.
47. Eirin A., Gloviczki M.L., Tang H., et al. Inflammatory and injury signals released from the post-stenotic human kidney. Eur Heart J 2013, 34(7):540-548a.
48. Eirin A., Gloviczki M.L., Tang H., et al. Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin. Nephrol Dial Transplant 2012, 27(11):4153-4161.
49. Kotliar C., Juncos L., Inserra F., et al. Local and systemic cellular immunity in early renal artery atherosclerosis. Clin J Am Soc Nephrol 2012, 7(2):224-230.
50. Gloviczki M.L., Keddis M.T., Garovic V.D., et al. TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis. Clin J Am Soc Nephrol 2013, 8(4):546-553.
51. Zhu X.Y., Daghini E., Chade A.R., et al. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol 2007, 18(4):1209-1217.
52. Ernandez T., Mayadas T.N. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int 2009, 76(3):262-276.
53. Saad A., Herrmann S.M., Crane J., et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv 2013, 6(4):428-435.
54. Chade A.R., Krier J.D., Galili O., Lerman A., Lerman L.O. Role of renal cortical neovascularization in experimental hypercholesterolemia. Hypertension 2007, 50(4):729-736.
55. Chade A.R., Mushin O.P., Zhu X., et al. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension 2005, 46(4):772-779.
56. Eddy A.A., Neilson E.G. Chronic kidney disease progression. J Am Soc Nephrol 2006, 17(11):2964-2966.
57. Keddis M.T., Garovic V.D., Bailey K.R., Wood C.M., Raissian Y., Grande J.P. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 2010, 25(11):3615-3622.
58. Cheng J., Zhou W., Warner G.M., et al. Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension. Am J Physiol Ren Physiol 2009, 297(4):F1055-F1068.
59. Kopp J.B., Factor V.M., Mozes M., et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996, 74(6):991-1003.
60. Baricos W.H., Cortez S.L., Deboisblanc M., Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999, 10(4):790-795.
61. Warner G.M., Cheng J., Knudsen B.E., et al. Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am J Physiol Renal Physiol 2012, 302(11):F1455-F1464.
62. Jin N., Wang Q., Zhang X., Jiang D., Cheng H., Zhu K. The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Int Immunopharmacol 2011, 11(9):1319-1326.
63. Wang D., Warner G.M., Yin P., et al. Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model. Am J Physiol Renal Physiol 2013, 304(7):F938-F947.
64. Levy B.I., Schiffrin E.L., Mourad J.J., et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008, 118(9):968-976.
65. Kang D.H., Kanellis J., Hugo C., et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002, 13(3):806-816.
66. Lemoine S., Rognant N., Collet-Benzaquen D., Juillard L. Nephrol Ther 2012, 8(4):206-211.
67. Hackstein N., Bauer J., Hauck E.W., Ludwig M., Kramer H.J., Rau W.S. Measuring single-kidney glomerular filtration rate on single-detector helical CT using a two-point Patlak plot technique in patients with increased interstitial space. Am J Roentgenol 2003, 181(1):147-156.
68. Lerman L.O. Imaging: BOLD assessment-effects of RAAS inhibition in CKD. Nat Rev Nephrol 2014, 10(5):247-248.
69. Warner L., Glockner J.F., Woollard J., Textor S.C., Romero J.C., Lerman L.O. Determinations of renal cortical and medullary oxygenation using blood oxygen level-dependent magnetic resonance imaging and selective diuretics. Invest Radiol 2011, 46(1):41-47.
70. Pedersen M., Dissing T.H., Morkenborg J., et al. Validation of quantitative BOLD MRI measurements in kidney: application to unilateral ureteral obstruction. Kidney Int 2005, 67(6):2305-2312.
71. Gomez S.I., Warner L., Haas J.A., et al. Increased hypoxia and reduced renal tubular response to furosemide detected by BOLD magnetic resonance imaging in swine renovascular hypertension. Am J Physiol Renal Physiol 2009, 297(4):F981-F986.
72. Gloviczki M.L., Glockner J.F., Lerman L.O., et al. Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension 2010, 55(4):961-966.
73. Saad A., Crane J., Glockner J.F., et al. Human renovascular disease: estimating fractional tissue hypoxia to analyze blood oxygen level-dependent MR. Radiology 2013, 268(3):770-778.
74. Michaely H.J., Metzger L., Haneder S., Hansmann J., Schoenberg S.O., Attenberger U.I. Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 2012, 81(7):684-689.
75. Chrysochou C., Mendichovszky I.A., Buckley D.L., Cheung C.M., Jackson A., Kalra P.A. BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease. Nephrol Dial Transplant 2012, 27(3):1013-1019.
76. Korsmo M.J., Ebrahimi B., Eirin A., et al. Magnetic resonance elastography noninvasively detects invivo renal medullary fibrosis secondary to swine renal artery stenosis. Invest Radiol 2013, 48(2):61-68.
77. Warner L., Yin M., Glaser K.J., et al. Noninvasive invivo assessment of renal tissue elasticity during graded renal ischemia using MR elastography. Invest Radiol 2011, 46(8):509-514.
78. Lee C.U., Glockner J.F., Glaser K.J., et al. MR elastography in renal transplant patients and correlation with renal allograft biopsy: a feasibility study. Acad Radiol 2012, 19(7):834-841.
79. James P.A., Oparil S., Carter B.L., et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
80. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice guidelines (Writing Committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006, 47(6):1239-1312.
81. Chade A.R., Zhu X., Lavi R., et al. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009, 119(4):547-557.
82. Ebrahimi B., Eirin A., Li Z., et al. Mesenchymal stem cells improve medullary inflammation and fibrosis after revascularization of swine atherosclerotic renal artery stenosis. PLoS One 2013, 8(7):e67474.
83. Kelsen S., Hall J.E., Chade A.R. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol 2011, 301(1):F218-F225.
84. Chade A.R., Kelsen S. Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. Circ Cardiovasc Interv 2010, 3(4):376-383.
85. Stewart N., Chade A.R. Renoprotective effects of hepatocyte growth factor in the stenotic kidney. Am J Physiol Renal Physiol 2013, 304(6):F625-F633.
86. Eirin A., Ebrahimi B., Zhang X., et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res 2014, 103(4):461-472.